Tafasitamab-lenalidomide for relapsed/refractory DLBCL: real-world data from the United States

The combination of tafasitamab and lenalidomide (tafa-len) is an effective treatment for patients with relapsed/refractory (R/R) DLBCL who are ineligible for intensive therapy. During ASH 2024, Dr Kim Saverno from the Incyte Corporation (Wilmington, DE, USA) presented real-life data with tafa-len in a cohort of 181 R/R DLBCL patients treated with this regimen across 23 centers in the US. The median age of patients in the study was 71 years, 52.5% had an ECOG performance status of 0-1 and 80% had an R-IPI score of 3-5 at the start of the tafa-len therapy. Overall, 71.8% of patients received tafa-len in 2^nd line. The real-world progression-free (PFS) and overall survival (OS) with tafa-len in this study were reported at 11.3 and 24.8 months, respectively. Across the entire study cohort, a real-world objective response rate of 73.5% was reported, including 23.2% of complete responses. Interestingly, a multivariate analysis of the real-world PFS and OS suggested a greater benefit for tafa-len in patients who received this therapy in 2^nd line compared to later treatment lines.